219,300 Shares in Arcturus Therapeutics Holdings Inc. $ARCT Purchased by Heartland Advisors Inc.

Heartland Advisors Inc. bought a new stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 219,300 shares of the biotechnology company’s stock, valued at approximately $1,474,000. Heartland Advisors Inc. owned 0.77% of Arcturus Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently modified their holdings of the business. Green Alpha Advisors LLC purchased a new position in Arcturus Therapeutics during the second quarter valued at approximately $182,000. Diversify Advisory Services LLC bought a new stake in Arcturus Therapeutics during the 2nd quarter valued at $91,000. BlackRock Inc. purchased a new position in shares of Arcturus Therapeutics in the 2nd quarter valued at $17,566,000. Deutsche Bank AG purchased a new position in shares of Arcturus Therapeutics in the 2nd quarter valued at $195,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Arcturus Therapeutics in the 2nd quarter worth $540,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Trading Up 22.4%

Shares of Arcturus Therapeutics stock opened at $13.45 on Friday. Arcturus Therapeutics Holdings Inc. has a 12-month low of $5.50 and a 12-month high of $24.17. The firm’s 50 day simple moving average is $7.09 and its two-hundred day simple moving average is $7.49. The firm has a market capitalization of $382.25 million, a price-to-earnings ratio of -4.06 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.16. The firm had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. On average, sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -3.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ARCT shares. Wall Street Zen raised Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.